PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis
Authors:
- Waleed HassanWaleed Hassan
- Doaa Mosad MosaDoaa Mosad Mosa
- Ayodele FaleyeAyodele Faleye
- Temesgen Teferi LibeTemesgen Teferi Libe
- Elisa PalalaneElisa Palalane
- Angela MigowaAngela Migowa
- Sulaiman Al MayoufSulaiman Al Mayouf
- Helen FosterHelen Foster
- Mohammed Hassan Abu-ZaidMohammed Hassan Abu-Zaid
- Soad HashadSoad Hashad
- Wafa HamdiWafa Hamdi
- Hanene Lassoued FerjaniHanene Lassoued Ferjani
- 5 January 2026
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 1323-1336
Abstract
Objective To present updated evidence-based recommendations with a range of therapeutic options for children in Africa with oligoarticular juvenile idiopathic arthritis (JIA), adopting the treat to-target approach. Methods This study was conducted by the Paediatric Society of the African League Against Rheumatism (PAFLAR) to reach a consensus for recommendations regarding diagnosis and management of oligoarticular JIA suitable for application among different African countries. The Delphi technique was used to reach a consensus of 15 key questions identified by the steering committee. According to the PICO (patient/population, intervention, comparison, outcome) approach, a voting process among 22 African and international clinicians and experts in the field of pediatric rheumatology was performed after intensive systematic review of literature. Results A consensus was reached for 15 recommendations for diagnosis, monitoring, management of the disease, and its complications, intervention, and when to discontinue treatment of oligoarticular JIA patients with high level of agreement (ranging between 85 and 95%) who agreed or strongly agreed, and the response rate was 100%. Conclusion These recommendations focus on the early diagnosis and multidisciplinary management of oligoarticular JIA and its complications with high levels of consensus and agreement, improving practice consistency among healthcare providers. Key Points • A panel of experts created a consensus about the early diagnosis of oligoarticular JIA • Consensus-based recommendations to the management of oligoarticular JIA • These guidelines emphasized on the oligoarticular JIA-specific characteristics, severity factors, and treatment alternativesKeywords
This publication has 71 references indexed in Scilit:
- 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic ArthritisArthritis Care & Research, 2022
- Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab GroupArthritis Care & Research, 2020
- Real‐World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian CohortArthritis Care & Research, 2019
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and EnthesitisArthritis Care & Research, 2019
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated UveitisArthritis Care & Research, 2019
- Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission DurationArthritis Care & Research, 2017
- Impact of Medication Withdrawal Method on Flare‐Free Survival in Patients with Juvenile Idiopathic Arthritis on Combination TherapyArthritis Care & Research, 2015
- American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritisArthritis Care & Research, 2011
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in RemissionA Randomized Clinical TrialJAMA, 2010